Valuation: Enzymatica AB

Market Cap 595M 533M 487M 445M 838M 55.9B 865M 5.88B 2.34B 29.83B 2.23B 2.18B 94.17B P/E 2024
-5.73x
P/E 2025 -8.89x
Enterprise Value 563M 505M 461M 421M 793M 52.88B 818M 5.56B 2.22B 28.22B 2.11B 2.07B 89.08B EV / Sales 2024
5.88x
EV / Sales 2025 7.96x
Free-Float
56.66%
Yield 2024 *
-
Yield 2025 -
1 day+8.89%
1 week+7.93%
Current month+7.93%
1 month+41.62%
3 months+32.79%
6 months-5.04%
Current year+28.95%
1 week 2.19
Extreme 2.19
2.64
1 month 1.66
Extreme 1.665
2.64
Current year 1.55
Extreme 1.55
3.4
1 year 1.55
Extreme 1.55
3.4
3 years 1.34
Extreme 1.34
5.45
5 years 1.34
Extreme 1.34
10.3
10 years 1.34
Extreme 1.34
24.7
Manager TitleAgeSince
Chief Executive Officer - 01/02/2026
Director of Finance/CFO - 13/04/2026
Chief Tech/Sci/R&D Officer - 27/08/2026
Director TitleAgeSince
Director/Board Member 60 01/05/2026
Chairman 64 19/12/2016
Director/Board Member 59 01/05/2021
Date Insider Type Main position Quantity % Market Cap. Importance
17/7/26 Buy

Chief Financial Officer

50,000 0.0206%
1/4/26 Sell

Responsable ventes & marketing

40,000 0.0165%
30/12/25 Buy

Chairman

20,000 0.0082%
Change 5-day change 1-year change 3-year change Capi.($)
+8.89%+7.93%+21.29%-35.78% 60.19M
-0.79%-4.48%+44.44%+127.49% 1,206B
+1.43%+1.11%+47.73%+82.08% 665B
+1.07%-1.21%+32.99%+106.31% 515B
-0.36%-3.25%+47.17%+64.58% 381B
-0.14%-1.87%+71.05%+40.63% 362B
-0.78%-0.52%+30.57%+57.98% 307B
-0.80%-0.21%+8.54%+35.56% 289B
+0.03%-1.20%+45.89%+68.76% 249B
-0.41%-2.22%+35.24%+105.68% 207B
Average +0.81%-0.59%+38.49%+65.33% 417.98B
Weighted average by Cap. -0.04%-1.96%+42.24%+88.38%

Financials

2024 2025
Net sales 45.58M 40.88M 37.36M 34.1M 64.25M 4.28B 66.28M 450M 180M 2.29B 171M 167M 7.22B 53.9M 48.35M 44.18M 40.33M 75.99M 5.07B 78.39M 533M 212M 2.7B 202M 198M 8.54B
Net income -53.18M -47.7M -43.59M -39.79M -74.97M -5B -77.33M -525M -210M -2.67B -200M -195M -8.42B -51.89M -46.54M -42.53M -38.83M -73.15M -4.88B -75.46M -513M -204M -2.6B -195M -191M -8.22B
Net Debt -73.01M -65.48M -59.85M -54.63M -103M -6.86B -106M -721M -288M -3.66B -274M -268M -11.56B -32.11M -28.8M -26.32M -24.03M -45.27M -3.02B -46.7M -317M -127M -1.61B -121M -118M -5.08B
Projected Income Statement - Annual - Enzymatica AB
Logo Enzymatica AB
Enzymatica AB (publ) is a Sweden-based life science company that develops and sells medical devices for infection-related diseases. The Company deals with research, development and sales of products based on enzyme technology and related activities. Enzymatica AB (publ) develops solutions that support the body's own defenses against virus, irritants and microorganisms. The Company offers products which are based on a barrier technology, includes marine enzymes. Enzymatica AB (publ) focuses on product development based on the tested and patented barrier technology used in the common cold product ColdZyme, a mouth spray that protects against colds, can help shorten the duration of the cold if used in the early stages of infection, relieves cold symptoms, and soothes sore throats.
Employees
17
Date Price Change Volume
06/11/26 SEK 2.450 +8.89% 79,009
05/11/26 SEK 2.250 -13.13% 321,093
04/11/26 SEK 2.590 +17.73% 566,593
03/11/26 SEK 2.200 -4.35% 49,613
02/11/26 SEK 2.300 +1.32% 181,642

Net sales - Rate of surprise

Rate of surprise - Net sales - Annual - Enzymatica AB
  1. Stock Market
  2. Stocks
  3. ENZY Stock